Actively Recruiting

Age: 14Years +
All Genders
NCT07309822

Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp.

Led by Probelte Pharma S.L.U. · Updated on 2025-12-30

27

Participants Needed

13

Research Sites

356 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy With Beltaven® With Apis mellifera, Polistes dominula or Vespula spp. allergic patients

CONDITIONS

Official Title

Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp.

Who Can Participate

Age: 14Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 14 years or older at the time of study inclusion
  • Signed informed consent by the patient or legal representative if minor
  • Signed assent form by minors when applicable
  • Allergy to Apis mellifera, Vespula spp., or Polistes dominula with systemic reaction after sting, involving multiple organs or only skin
  • Positive intradermal test with Beltaven� diagnostic showing mean wheal diameter  5 mm
  • Positive specific IgE test from class 1 onwards ( 0.35 kUA/L)
  • Willingness to receive immunotherapy with Beltaven�
Not Eligible

You will not qualify if you...

  • Severe cardiovascular diseases, active malignancies, or malignancies in remission within last 5 years
  • Non-stabilized systemic or organ-specific autoimmune diseases
  • Severe mental disorders or other significant chronic diseases affecting study results
  • Known allergy to any vaccine excipients
  • Pregnancy, breastfeeding, or planning pregnancy during study
  • Received hymenoptera immunotherapy within 5 years before or during study
  • Receiving immunotherapy with a different allergen during study
  • Sensitization to two or more hymenoptera species confirmed by CAP inhibition testing
  • Conditions like thrombocytopenic purpura, vasculitis, rhabdomyolysis, or renal failure

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 13 locations

1

Hospital Universitario Vall d' Hebron

Barcelona, Barcelona, Spain

Actively Recruiting

2

Hospital Universitario de Bellvitge

Barcelona, Spain

Actively Recruiting

3

Xarxa Assistencial I Universitària de Manresa

Barcelona, Spain

Actively Recruiting

4

Hospital General Universitario de Castellón

Castellon, Spain

Actively Recruiting

5

Hospital General la Mancha Centro

Ciudad Real, Spain

Actively Recruiting

6

Hospital General Universitario de Ciudad Real

Ciudad Real, Spain

Actively Recruiting

7

Hospital Universitario Reina Sofía

Córdoba, Spain

Actively Recruiting

8

Hospital Santa Caterina de Girona

Girona, Spain

Actively Recruiting

9

Hospital Universitario Santa María de Lleida

Lleida, Spain

Actively Recruiting

10

Hospital Universitario Fundación Alcorcón

Madrid, Spain

Actively Recruiting

11

Hospital Universitario la Paz

Madrid, Spain

Actively Recruiting

12

Hospital Universitario Ramón y Cajal

Madrid, Spain

Actively Recruiting

13

Hospital Vega Baja

Orihuela, Spain

Actively Recruiting

Loading map...

Research Team

I

Inmaculada Buendía Jiménez, DVM

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study to Assess the Safety and Effectiveness of Beltaven® in Patients With Allergy to Apis Mellifera, Polistes Dominula or Vespula Spp. | DecenTrialz